プロットキン ワクチン(第7版)Plotkin's Vaccines

Dummy

プロットキン ワクチン(第7版)Plotkin's Vaccines

7TH

Orenstein, Walter A./Offit, Paul A./Edwards, Kathryn M.

Elsevier - Health Sciences Division 2017/06 発行
1720 p. 600 illus.
装丁: HRD 装丁について
版表示など: HRD
テキストの言語: ENG 出版国: US
ISBN: 9780323357616
KCN: 1028212069

標準価格:¥81,089(本体 ¥73,718)   
Web販売価格あり Web販売価格について


この商品は出版社からの取り寄せとなります。品切れの場合もありますので、恐れ入りますがご了承下さい。

納期について
DDC:
615.372
KDC:
G44 免疫・アレルギー・感染症・微生物
G56 感染症
G451 薬学一般
G901 予防医学

ブックニュースNo:ND1296
関連書リスト: SB3100B ND1402 SB3101A ND1446 ND1451

ご購入を希望される方は、
下のリンクをクリックしてください。

To_buy_link

Annotation

ワクチンと感染症の究極の百科事典、プロットキンの改訂第7版。最先端のワクチンと感染症に関する全ての知見を網羅。
This award-winning text offers a complete understanding of each disease, as well as the latest knowledge of both existing vaccines and those currently in research and development. Prev. ed.: 2012.

Full Description

From the development of each vaccine to its use in reducing disease, Plotkin's Vaccines, 7th Edition, provides the expert information you need to provide optimal care to your patients. This award-winning text offers a complete understanding of each disease, as well as the latest knowledge of both existing vaccines and those currently in research and development. Described by Bill Gates as "an indispensable guide to the enhancement of the well-being of our world," Plotkin's Vaccines is a must-have reference for current, authoritative information in this fast-moving field.

Includes complete information for each disease, including clinical characteristics, microbiology, pathogenesis, diagnosis, and treatment, epidemiology, and public health and regulatory issues - plus complete information for each vaccine, including its stability, immunogenicity, efficacy, duration of immunity, adverse events, indications, contraindications, precautions, administration with other vaccines, and disease-control strategies.
Analyzes the cost-benefit and cost-effectiveness of different vaccine options.
Helps you clearly visualize concepts and objective data through an abundance of tables and figures.

Covers the new oral cholera and zoster vaccines, as well as newly licensed meningococcal group B vaccines and a newly licensed dengue vaccine.
Brings you up to date on successful human trials of Ebola vaccines, an enterovirus 71 vaccine licensed in China, and new recommendations and changes to polio vaccines.
Features a new chapter on maternal immunization.
Expert ConsultT eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, and references from the book on a variety of devices.

Table of Contents

Section 1: General Aspects of Vaccination

1. A Short History of Vaccination

2. Vaccine Immunology

3. Correlates of Protection

4. The Vaccine Industry

5. Vaccine Manufacturing

6. Evolution of Adjuvants Across the Centuries

7. Vaccine Additives and Manufacturing Residuals in Vaccines Licensed in the United States

8. Passive Immunization

9. General Immunization Practices

Section 2: Licensed Vaccines and Vaccines in Development

10. Adenovirus Vaccines

11. Anthrax Vaccines

12. Biodefense and Special Pathogen Vaccines

13. Cancer Vaccines

14. Cholera Vaccines

15. Combination Vaccines

16. Cytomegalovirus Vaccines

17. Dengue Vaccines

18. Diarrhea Caused by Bacteria

19. Diphtheria Toxoid

20. Ebola Vaccines

21. Enterovirus 71

22. Epstein-Barr Virus Vaccines

23. Haemophilus influenzae Type b Vaccines

24. Hepatitis A Vaccines

25. Hepatitis B Vaccines

26. Hepatitis C Vaccines

27. Hepatitis E Vaccines

28. Herpes Simplex Virus Vaccines

29. Human Immunodeficiency Virus Vaccines

30. Human Papillomavirus Vaccines

31. Inactivated Influenza Vaccines

32. Influenza Vaccine-Live

33. Japanese Encephalitis Vaccines

34. Lyme Disease Vaccines

35. Malaria Vaccines

36. Maternal Immunization

37. Measles Vaccines

38. Meningococcal Capsular Group A, C, W, and Y Conjugate Vaccines

39. Meningococcal Capsular Group B Vaccines

40. Mumps Vaccines

41. Noninfectious Disease Vaccines

42. Norovirus Vaccines

43. Parasitic Disease Vaccines

44. Pertussis Vaccines

45. Plague Vaccines

46. Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines

47. Pneumococcal Polysaccharide Vaccines

48. Poliovirus Vaccine-Inactivated

49. Poliovirus Vaccine-Live

50. Rabies Vaccines

51. Respiratory Syncytial Virus Vaccines

52. Rotavirus Vaccines

53. Rubella Vaccines

54. Smallpox and Vaccinia

55. Staphylococcus aureus Vaccines

56. Streptococcus Group A Vaccines

57. Streptococcus Group B Vaccines

58. Tetanus Toxoid

59. Tickborne Encephalitis Vaccines

60. Tuberculosis Vaccines

61. Typhoid Fever Vaccines

62. Varicella Vaccines

63. Yellow Fever Vaccines

64. Zika Virus

65. Zoster Vaccines

Section 3: New Technologies

66. Technologies for Making New Vaccines

67. Development of Gene-Based Vectors for Immunization

68. Technologies to Improve Immunization

Section 4: Vaccination of Special Groups

69. Vaccination of Immunocompromised Hosts

70. Vaccination of Human Immunodeficiency Virus-Infected Persons

71. Vaccines for International Travel

72. Vaccines for Healthcare Personnel

Section 5: Public Health and Regulatory Issues

73. Immunization in the United States

74. Immunization in Europe

75. Immunization in the Asia-Pacific Region

76. Immunization in Developing Countries

77. Community Protection

78. Economic Analyses of Vaccine Policies

79. Regulation and Testing of Vaccines

80. Regulation of Vaccines in Europe

81. Regulation of Vaccines in Low- and Middle-Income Countries

82. Vaccine Safety

83. Legal Issues

84. Ethics

Appendix: Websites and Applications for Mobile Devices with Information about Immunization

▲ページトップへ